LGND

LIGAND PHARMACEUTICA

Health Care·Pharmaceuticals·$4.6B

Reported·Q3-2015

Ligand Pharmaceuticals Beats on EPS, Stock Up 1.88%

Metric	Actual	Expected	Surprise
EPS	$0.56	N/A	+166.67%
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

More Earnings This Week

BAMReported

BROOKFIELD ASSET MGM Class A

Nov 6, 2015

CIReported

THE CIGNA GROUP

Nov 6, 2015

MTReported

ARCELORMITTAL ADR

Nov 6, 2015

SATSReported

ECHOSTAR CORP Class A

Nov 6, 2015

HUM

Management Commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook regarding earnings performance. However, they did not provide specific guidance for future quarters.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They highlighted ongoing projects and their potential impact on future earnings.

What It Means

Ligand Pharmaceuticals reported a strong earnings per share, significantly exceeding expectations. The stock reacted positively, rising by 1.88%. The lack of revenue figures and guidance may leave some investors cautious, but the EPS beat suggests underlying strength in the company's operations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime